Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Lyell Immunopharma (Nasdaq: LYEL) announced that senior management will join a fireside chat at the H.C.

Rhea-AI Summary

Lyell Immunopharma (Nasdaq: LYEL) announced that senior management will join a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 1:30 p.m. ET.

A live webcast and replay will be available in the Investors section of Lyell’s website.

Argus Jun 25 session

-3.92% close to close Open Argus

Details

News Market Reaction – LYEL

On Jun 25, the day this news came out, LYEL closed 3.92% below the previous close.

Data tracked by StockTitan Argus for the Jun 25 session.

Key Figures

Conference date: June 30, 2026 Fireside chat time: 1:30 pm Eastern Time Conference edition: 4th Annual

Conference date

June 30, 2026

H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Fireside chat time

1:30 pm Eastern Time

Scheduled start time for Lyell management session

Conference edition

4th Annual

H.C. Wainwright Cell Therapy Virtual Conference

Historical Context

5 past events · Latest: Jun 12

5 events

1. Jun 12

   Clinical data update

   24h Move

   -2.0%

   Updated safety and translational data for ronde-cel in large B-cell lymphoma.

2. Jun 08

   Trial design change

   24h Move

   +2.8%

   Phase 1 LYL273 trial amended to Phase 1/2 with expanded patient cohorts.

3. Jun 04

   Conference presentation

   24h Move

   -8.3%

   Planned Phase 1/2 ronde-cel safety and translational data presentations at EHA 2026.

4. Jun 01

   Investor conference

   24h Move

   -1.0%

   Participation in Goldman Sachs Global Healthcare Conference with fireside chat webcast.

5. May 12

   Investor outreach

   24h Move

   +0.3%

   Participation in two May oncology-focused investor conferences with webcasts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

car t-cell therapies, chimeric antigen receptor, webcast

3 terms

car t-cell therapies medical

"advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients"

CAR T-cell therapies are treatments that remove a patient’s immune cells, reprogram them to recognize specific cancer markers, and return them to the body so they act like specially trained soldiers hunting tumor cells. They matter to investors because they can offer powerful, long-lasting benefits for hard-to-treat cancers but come with high development, manufacturing and regulatory costs, pricing and reimbursement uncertainty, and concentrated market risk that can drive big gains or losses.

chimeric antigen receptor medical

"advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients"

A chimeric antigen receptor is an engineered protein added to a patient’s immune cells that gives them a new, specific ability to recognize and attack cells carrying a particular marker (antigen) — like equipping police with a facial‑recognition app to find a suspect. For investors, CARs are the core technology behind targeted cell therapies: their clinical success, manufacturing complexity, safety profile, and regulatory approval determine treatment market potential, development costs, and company value.

webcast technical

"A live webcast of the fireside chat and subsequent replay can be accessed"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 4^th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 1:30 pm Eastern Time.

A live webcast of the fireside chat and subsequent replay can be accessed through the Investors section of the Company’s website at www.lyell.com.

About Lyell Immunopharma, Inc.

Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T-cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. LyFE has commercial launch capability and is expected to have the capacity to manufacture more than 1,200 CAR T-cell doses per year. To learn more, please visit www.lyell.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell management’s planned participation at an investor conference; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 6, 2026. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.

Contact:

Pablo Fenton
Associate Director, Investor Relations and Corporate Communications
pfenton@lyell.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Lyell Immunopharma (LYEL) present at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference?

Lyell Immunopharma will participate in a fireside chat on June 30, 2026, at 1:30 p.m. Eastern Time. According to Lyell, the session is part of the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference for investors and industry participants.

How can investors access the Lyell Immunopharma (LYEL) webcast for the June 30, 2026 cell therapy conference?

Investors can access Lyell Immunopharma’s live webcast through the Investors section of the company’s website, www.lyell.com. According to Lyell, a replay of the June 30, 2026 fireside chat will also be available online after the conference session.

What will Lyell Immunopharma (LYEL) management discuss at the H.C. Wainwright cell therapy virtual conference?

Lyell senior management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. According to Lyell, the company is a late-stage clinical business advancing next-generation CAR T-cell therapies for patients with cancer, a likely focus for discussion.

What type of company is Lyell Immunopharma (LYEL) participating in the June 30, 2026 virtual conference?

Lyell Immunopharma is described as a late-stage clinical company developing next-generation CAR T-cell therapies for cancer patients. According to Lyell, participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference highlights its focus on innovative chimeric antigen receptor T-cell treatments.

Where is Lyell Immunopharma (LYEL) headquartered and how is it involved in CAR T-cell therapy?

Lyell Immunopharma is based in South San Francisco, California, and focuses on CAR T-cell therapies. According to Lyell, it is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor T-cell treatments for patients with cancer.